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1726-4Benefit or harm: Does age matter in stroke outcome after
thrombolysis?In the past several decades, stroke has been the second most
common cause of mortality worldwide.1 Currently, it is the third
leading cause of global disease burden estimated by disability-
adjusted life years.2 Stroke remains the leading cause of dis-
ability in elderly individuals.3 Therefore, stroke is a substantial
public health concern and poses a tremendous socioeconomic
burden. Stroke prevention should be a major focus of health
care. However, in the absence of effective preventive programs,
a complementary acute stroke care policy, especially for acute
stroke management, is critically important.
In excess of 80% of strokes are of the ischemic type.
Intravenous (IV) administration of recombinant tissue plasmi-
nogen activator (rt-PA) within 3 hours of symptom onset is the
only approved medical therapy for patients with acute ischemic
stroke.4,5 However, there are currently few proven treatment
options for very elderly people, and only 42 patients over 80
years of age have been recruited in randomized controlled trials
(RCTs) for rt-PA.5 With the ever-growing elderly population,
stroke risk is expected to increase, together with life expect-
ancy.6 An estimated 30% of strokes occur in patients over 80
years of age, but the safety and efficacy profiles of IV rt-PA in
this age group remain unclear.4,7 The European Cooperative
Acute Stroke Study (ECASS) trial specifically excluded this age
group for fear of excessive symptomatic intracranial hemor-
rhage.7 Advancing age is associated with increased in-hospital
mortality8 and hemorrhage risk9 in stroke patients treated
with rt-PA. However, older stroke patients also demonstrate
higher stroke mortality without rt-PA treatment, and are less
likely to recover than younger stroke patients. Thus, older age
should not be a contraindication in thrombolytic therapy.
Unfortunately, as stated above, RCT data on the safety and
efficacy of thrombolysis in patients over 80 years of age are
limited, although this age group accounts for nearly one-third
of stroke admissions in developed countries. Therefore, reli-
able data are needed to ensure that therapy is provided to
appropriately selected older patients and to improve poor
outcomes from stroke in this aging segment of the population.
Because there is a lack of RCT-based data regarding the
efficacy of rt-PA within 3 hours of symptom onset in elderly
stroke patients, other sources of data may be used to judge the
appropriateness of thrombolytic therapy in this population.
Recent cohort studies and meta-analyses comparing treat-
ment with IV rt-PA in stroke patients aged >80 years withx.doi.org/10.1016/j.jcma.2014.02.003
901/Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Assyounger (80 years of age) stroke patients showed incon-
sistent findings.10e12 Chen et al retrospectively analyzed a
cohort of 183 patients receiving thrombolytic therapy, of
whom 56 were in the aged group (>80 years).10 There were no
significant differences in stroke risk factors between these two
groups, except that the aged group contained more female
patients. However, the baseline National Institute of Health
Stroke Scale (NIHSS) score was insignificantly higher in the
aged group. In addition, there was a trend toward a lower
percentage of aged patients returning home after stroke.
Despite these differences, this study showed similar recanali-
zation rates, symptomatic intracranial hemorrhage rates, and
short-term outcomes between patients over 80 years of age and
younger patients.
The largest prospective observational study of thrombolytic
outcomes to date (the Safe Implementation of Treatment in
Stroke International Stroke Thrombolysis Register, SITS-
ISTR)11 included 1831 patients aged >80 years and 19,411
patients aged80 years. Compared to the younger age group, the
aged group demonstrated greater stroke severity, a lower level of
pre-stroke independence, and included a larger proportion of
women. After 3months, the aged group exhibited a higher rate of
mortality and poorer functional outcomes (as determined by a
score >2 on the modified Rankin Scale). Similar conclusions
were also reached in a recent meta-analysis.12
Therefore, which factors may be used to predict 3-month
functional outcome? In addition to baseline NIHSS score,
hemorrhagic transformation (HT), and age, early neurologic
improvement (ENI) may play a role in stroke outcome.10,11,13,14
A post-hoc explorative analysis of the National Institute of
Neurological Disorders and Stroke (NINDS) rt-PA trial showed
that minor degrees of NI (3 points on the NIHSS) were seen
frequently in both the patient and placebo groups.4 Greater
degrees ofNI (4 points on theNIHSS or anNIHSS score of 0 at
24 hours after thrombolytic therapy) should be regarded as ENI.
Dramatic early improvement also might be a marker of recan-
alization after thrombolytic therapy and predictive of good
functional outcomes, irrespective of age group.10 Lack of ENI
was also associatedwith poor outcomes and death at 3months.13
However, another study showed that age and time to treatment
were predictors of major neurological improvement after
thrombolysis.14 So, whether older age may be associated with
lack of ENI is still controversial.ociation. All rights reserved.
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Association, Ong et al15 report on ENI in an aged (80 years)
population. From January 2007 to December 2012, a total of 157
patients with acute ischemic stroke received IV rt-PA therapy; of
these patients, 17 were 80 years of age. Seventy-eight aged
patients received no thrombolytic therapy. The rates of ENI, NI at
discharge, HT, and symptomatic HT were similar between the
treated older and younger groups. Of the aged population, the NI
at discharge rate was significantly higher in the thrombolytic
group than in the nonthrombolytic group. The authors suggested
that thrombolytic therapy may be feasible in the older patients.
From February 2009 to October 2013, a total of 103 acute
ischemic stroke patients received IV rt-PA therapy in Taipei
Veterans General Hospital, of whom 23 were aged >80 years
(9 women; mean age: 84.6 3.4 years, range: 81e95 years).
NIHSS scores at baseline (12.2 7.8 vs. 12.4 6.9) and 24
hours after thrombolytic therapy (10.4 7.5 vs. 9.8 6.8)
were similar between the two groups. Therefore, patients over
80 years of age and younger patients had similar recanaliza-
tion, short-term improvement, and HT rates after IV rt-PA.
Large-scale RCTs are needed to test the safety and efficacy
profiles in this particular patient population.
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